Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.

Trial Details

NCT ID
NCT07722754
Phase
PHASE2
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Cetuximab
  • Irinotecan
  • Bevacizumab
  • Sintilimab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Metastatic and unresectable colorectal adenocarcinom;
  • RAS wild-type and MSS tumor;
  • Measurable lesions;
  • Failed to at least two lines of standard treatment containing fluoropyrimidine, irinotecan and bevacizumab;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →